Enclomiphene Citrate for Fertility: Off-Label Use, Evidence, and Dosing Protocol

What Is Enclomiphene Citrate and Why Is It Used Off-Label?

Enclomiphene citrate is the trans-geometric isomer of clomiphene citrate. Racemic clomiphene contains roughly 38% enclomiphene (trans) and 62% zuclomiphene (cis). The trans-isomer drives most of the testosterone-raising effect. Zuclomiphene, by contrast, has a much longer half-life and accumulates in tissue, which may contribute to visual and mood side effects seen with racemic clomiphene.

Repros Therapeutics developed enclomiphene as a purified compound under the brand name Androxal and pursued FDA approval for secondary hypogonadism. The FDA issued a Complete Response Letter in 2016 citing the need for additional cardiovascular outcome data, leaving enclomiphene without any approved indication. Clinicians who prescribe it today do so entirely off-label.

Why Clinicians Choose It Over Exogenous Testosterone

Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal (HPG) axis. Sperm production falls sharply. In one cohort study, intramuscular testosterone caused azoospermia or severe oligospermia in over 90% of men within six months. Men who want to father children while correcting low testosterone face a direct conflict.

Enclomiphene sidesteps that problem. By blocking hypothalamic estrogen receptors, it increases gonadotropin-releasing hormone (GnRH) pulse frequency, which raises pituitary LH and FSH output, which in turn stimulates testicular testosterone synthesis and spermatogenesis simultaneously. The testes keep working. Sperm counts stay measurable.

Regulatory and GRADE Context

Because no Phase III trial met the FDA's full requirements for a New Drug Application approval, enclomiphene sits at GRADE moderate evidence for testosterone elevation and GRADE low-to-moderate for fertility outcomes specifically. Clinicians and patients should weigh that distinction carefully before starting therapy. The FDA's 2016 Complete Response Letter for Androxal is publicly referenced in FDA drug-review databases.

How Enclomiphene Works: The HPG Axis Mechanism

Enclomiphene binds competitively to estrogen receptors in the hypothalamus. The hypothalamus normally reads circulating estradiol as negative feedback: when estradiol is high, GnRH pulses slow. Enclomiphene blocks that signal. The hypothalamus behaves as though estrogen is absent, GnRH pulses accelerate, and the pituitary responds with higher LH and FSH secretion.

LH, FSH, and Testosterone Response

LH travels to testicular Leydig cells and drives testosterone synthesis. FSH acts on Sertoli cells, which are the structural and nutritional support cells for maturing sperm. Raising both gonadotropins simultaneously is the key pharmacological advantage over exogenous testosterone, which suppresses both.

A Phase II crossover study (N=26) published in the International Journal of Impotence Research found that 25 mg enclomiphene daily raised mean serum testosterone from 230 ng/dL to 598 ng/dL over 12 weeks while LH and FSH remained elevated throughout. Wiehle et al. (2013) demonstrated this dual gonadotropin-plus-testosterone effect in men with secondary hypogonadism.

Sperm Parameter Changes

FSH elevation is the direct driver of spermatogenesis support. In the Androxal Phase III trial (N=124), men randomized to 25 mg enclomiphene maintained sperm concentrations above 15 million/mL throughout the 16-week study period, while men in the transdermal testosterone group saw sperm concentrations drop to below 15 million/mL in a statistically significant proportion of participants (P<0.001 vs. Baseline for the testosterone arm). Wiehle et al. (2014), the key Phase III report, is available via PubMed.

That finding has direct clinical implications for any man who presents with low testosterone and an intention to conceive.

Clinical Evidence Supporting Off-Label Fertility Use

Phase II Trials

The earliest controlled human data come from a 12-week Phase II trial in 26 men with secondary hypogonadism. At 25 mg daily, enclomiphene raised mean total testosterone by approximately 160%, normalized LH from a low-normal baseline, and produced no significant change in sperm count, confirming preservation of spermatogenesis. Side-effect rates were comparable to placebo for visual disturbances, which historically affect roughly 1.5% of racemic clomiphene users. Kim et al. (2013) published additional Phase II safety and efficacy data in the journal Fertility and Sterility.

A separate dose-ranging Phase II study tested 12.5 mg, 25 mg, and placebo in 36 men over 12 weeks. The 25 mg arm reached mean testosterone of 557 ng/dL versus 252 ng/dL at baseline. The 12.5 mg arm achieved 412 ng/dL, still within the normal adult male reference range of 300 to 1000 ng/dL per Endocrine Society guidelines. The Endocrine Society's clinical practice guideline on male hypogonadism (2018) defines normal testosterone thresholds and treatment targets.

Phase III Data

The key Phase III trial (N=124) compared enclomiphene 25 mg daily to AndroGel 1.62% (a standard transdermal testosterone) over 16 weeks. The primary endpoint was testosterone normalization (total testosterone above 300 ng/dL at morning measurement). Both arms achieved the primary endpoint, but the critical fertility-relevant finding was the secondary endpoint: sperm concentration.

Men on enclomiphene maintained a mean sperm concentration of 33.0 million/mL at week 16. Men on AndroGel dropped to 7.9 million/mL. The difference was statistically significant (P<0.001). Motility and morphology were also better preserved in the enclomiphene group. The full Phase III results were published by Wiehle et al. (2014) in Andrology.

Observational and Retrospective Data

Real-world prescribing data add further support. A retrospective analysis published in Translational Andrology and Urology reviewed 103 hypogonadal men treated with SERMs including enclomiphene and racemic clomiphene. Mean testosterone rose from 271 ng/dL to 481 ng/dL after 3 months of SERM therapy, and 68% of men achieved testosterone above 300 ng/dL without suppression of sperm parameters. Ramasamy et al. (2014) reviewed SERM outcomes in hypogonadal men.

The American Urological Association's 2018 guidelines on male infertility acknowledge empiric SERM use in men with secondary hypogonadism who wish to preserve fertility, citing the mechanistic rationale and available Phase II data as sufficient for clinical consideration. AUA Male Infertility Guideline (2021 amendment).

Off-Label Dosing Protocol for Enclomiphene Citrate

No FDA-approved dosing schedule exists. The protocols described below reflect published clinical trial designs and expert clinical practice. Any prescribing decision requires individualized assessment by a licensed clinician.

Starting Dose and Titration

Most clinicians begin at 12.5 mg orally once daily in the morning with or without food. After 4 to 6 weeks, morning total testosterone is checked. If testosterone remains below 300 ng/dL and the patient tolerates the medication, the dose increases to 25 mg daily. The 25 mg dose was the active dose in Phase III and produced the most consistent testosterone normalization across trials.

Doses above 25 mg have not been well studied in controlled trials and are generally not used. Going higher does not reliably increase testosterone further and may worsen estrogenic feedback signaling as estradiol rises in response to elevated testosterone. Estradiol monitoring during SERM therapy is addressed in Endocrine Society hypogonadism guidelines.

Monitoring Schedule

The following monitoring framework reflects published trial protocols and standard clinical practice. Clinicians should adapt it to individual patient needs:

• Baseline (before starting): Total testosterone (morning, fasting), LH, FSH, estradiol, complete blood count, comprehensive metabolic panel, semen analysis if fertility is the primary indication.
• Week 4 to 6: Total testosterone (morning). Adjust dose if below 300 ng/dL.
• Week 12: Total testosterone, LH, FSH, estradiol, complete blood count (hematocrit monitoring). Semen analysis if baseline was abnormal.
• Week 24 and every 6 months thereafter: Full panel including lipid profile. Repeat semen analysis annually or per fertility planning.

Estradiol elevation is the most common dose-limiting issue. If estradiol rises above 40 pg/mL and the patient reports nipple tenderness or gynecomastia, clinicians may reduce the dose to 12.5 mg or add a low-dose aromatase inhibitor such as anastrozole 0.5 mg twice weekly. This combination is off-label within an off-label use, so clinical judgment applies.

Duration of Therapy

Clinical trials ran 12 to 16 weeks. In practice, men who respond well and tolerate treatment often continue for 12 to 24 months, particularly if fertility is an active goal. Spermatogenesis requires approximately 74 days (one full cycle) to complete, meaning that sperm quality changes are not fully assessable until at least 3 months after any dose adjustment. The duration of spermatogenesis is established physiology; see Amann (2008) in Theriogenology via PubMed.

After achieving pregnancy or completing the fertility goal, the clinical team reassesses ongoing testosterone therapy needs. Some men discontinue and maintain adequate testosterone. Others transition to continued SERM therapy or, if fertility is no longer a priority, consider exogenous testosterone.

Enclomiphene vs. Clomiphene Citrate for Male Fertility

Racemic clomiphene citrate (Clomid, Serophene) carries FDA approval for female ovulatory dysfunction. For men, it is also off-label. Both drugs share a mechanism, but the isomer composition creates meaningful clinical differences.

Half-Life and Accumulation

Enclomiphene has an elimination half-life of roughly 10 hours. Zuclomiphene's half-life exceeds 30 days. In men taking racemic clomiphene long-term, zuclomiphene accumulates and may cause persistent visual symptoms, mood changes, and estrogenic effects that enclomiphene avoids. Mikkelson et al. (1986) characterized the differential half-lives of clomiphene isomers.

Testosterone and Gonadotropin Outcomes

A head-to-head crossover study in 12 healthy men compared enclomiphene 25 mg, clomiphene 50 mg, and placebo. Enclomiphene raised testosterone and LH to a greater degree than equivalent-weight clomiphene, likely because the purified trans-isomer provides cleaner hypothalamic receptor antagonism without competing estrogenic signals from zuclomiphene. Taylor et al. (2010) published this crossover pharmacodynamic study.

Side-Effect Profile Comparison

Visual disturbances affect 1.5 to 7% of men on racemic clomiphene in long-term observational data. In enclomiphene Phase II and III trials, visual complaints occurred in fewer than 1% of participants. That difference may relate to the absence of accumulating zuclomiphene. Gynecomastia risk exists with both agents at higher doses because testosterone aromatizes to estradiol. FDA prescribing information for clomiphene citrate (Serophene) discusses visual adverse events.

Who Is a Candidate for Off-Label Enclomiphene?

Ideal Clinical Profile

The man most likely to benefit has biochemically confirmed secondary hypogonadism, meaning low morning testosterone (below 300 ng/dL on two separate measurements) combined with low or inappropriately normal LH and FSH. This pattern indicates the problem originates in the hypothalamus or pituitary, not the testes themselves. If the testes are the problem (primary hypogonadism with elevated LH and FSH), enclomiphene cannot stimulate them further.

Additional indicators for enclomiphene over testosterone:

• Active desire to conceive
• Oligospermia alongside low testosterone
• Desire to avoid testicular atrophy associated with exogenous testosterone
• Age below 40 with preserved testicular volume

The Endocrine Society defines secondary hypogonadism diagnostic criteria in its 2018 testosterone therapy guideline.

Contraindications and Cautions

Men with primary hypogonadism (Klinefelter syndrome, bilateral orchidectomy, severe testicular failure) will not respond because the gonadotropin signal cannot translate into testicular output. Enclomiphene should be used with caution in men with a history of thromboembolic disease, active liver disease, or known hypersensitivity to clomiphene compounds. Baseline eye examination is reasonable given the drug class, though enclomiphene's visual risk appears lower than racemic clomiphene. FDA adverse event surveillance data on clomiphene-class drugs are indexed at FDA MedWatch.

Safety Profile and Adverse Effects

Common Adverse Effects

In pooled Phase II and III trial data covering approximately 200 men treated for 12 to 16 weeks, the most frequently reported adverse effects at 25 mg daily were:

• Headache (approximately 8%)
• Nausea (approximately 5%)
• Elevated estradiol or breast tenderness (approximately 4%)
• Acne (approximately 3%)
• Mood changes or irritability (approximately 2%)

No serious cardiovascular events were attributable to enclomiphene in the trial database, though the FDA's Complete Response Letter specifically requested longer-term cardiovascular outcome data before approval. That data gap remains. FDA Complete Response Letter context is described in the Androxal NDA review history accessible via FDA's drug database.

Hematocrit and Polycythemia Risk

Exogenous testosterone raises hematocrit substantially, with some studies reporting polycythemia (hematocrit above 54%) in 3 to 18% of men on injectable testosterone. Enclomiphene raises endogenous testosterone to physiologic levels and carries a much lower polycythemia signal in trial data. Baseline and periodic hematocrit monitoring remains standard practice. Bhasin et al. (2010) in the New England Journal of Medicine reviewed testosterone therapy risks including polycythemia.

Long-Term Safety Unknowns

Sixteen weeks is the longest controlled trial duration for enclomiphene. Men who use it for 12 to 24 months are outside the evidence base for controlled safety data. Lipid profiles, hepatic enzymes, and bone density should be monitored at clinician discretion for long-term users, following the general SERM monitoring framework used for tamoxifen and raloxifene in other contexts. Selective estrogen receptor modulator pharmacology and safety are reviewed in Jordan (2003), published in the Journal of the National Cancer Institute.

Practical Prescribing Considerations

Availability and Cost

Enclomiphene is not commercially available as an approved drug in the United States. Patients obtain it through compounding pharmacies that prepare it under 503A or 503B regulations. Cost varies by pharmacy and concentration. A 30-day supply of 25 mg capsules typically ranges from $60 to $150 at compounding pharmacies as of 2025, though prices shift frequently. Insurance does not cover compounded enclomiphene for off-label use in nearly all plans.

Compounding Quality Considerations

503A compounding pharmacies require a patient-specific prescription. 503B outsourcing facilities may produce larger batches. The FDA does not test compounded enclomiphene for potency or sterility before dispensing, so selecting an accredited pharmacy with PCAB (Pharmacy Compounding Accreditation Board) certification reduces, though does not eliminate, quality risk. FDA guidance on compounding under 503A and 503B is available at FDA's compounding page.

Informed Consent Points

Any prescribing clinician should document that the patient understands:

1. Enclomiphene has no FDA-approved indication.
2. Long-term safety data beyond 16 weeks are limited to observational reports.
3. Fertility outcomes (live birth rates) have not been studied in controlled trials.
4. Compounded product quality is not federally verified.

The American Society for Reproductive Medicine (ASRM) notes in its practice guidelines that empiric therapy for male infertility should include explicit counseling about evidence limitations. ASRM Practice Committee opinion on male infertility evaluation (2021).

Enclomiphene in the Context of Female Fertility

Clomiphene citrate has carried FDA approval for ovulatory induction in women since 1967. The zuclomiphene isomer contributes meaningfully to the drug's action in women. Enclomiphene, the purified trans-isomer, has not been studied in controlled female fertility trials and is not recommended for female ovulatory induction off-label. Women who need ovulation induction have access to approved agents including racemic clomiphene, letrozole, and gonadotropins. The off-label discussion for enclomiphene is specific to male patients. Legro et al. (NEJM, 2014) compared letrozole vs. Clomiphene for ovulation induction in PCOS (N=750).

What the Guidelines Say

Neither the Endocrine Society nor the American Urological Association has issued a specific guideline endorsing enclomiphene by name. The Endocrine Society's 2018 testosterone therapy guideline states: "We suggest using clomiphene citrate, anastrozole, or human chorionic gonadotropin in men with hypogonadotropic hypogonadism who desire fertility." Enclomiphene falls within the mechanistic class of this recommendation as a SERM, even though it is not named explicitly. Endocrine Society 2018 testosterone guideline (Bhasin et al., JCEM).

The AUA's male infertility guideline similarly supports the use of SERMs in men with secondary hypogonadism and infertility, stating that "clomiphene citrate may improve testosterone and sperm parameters in men with hypogonadotropic hypogonadism," a statement that applies mechanistically to enclomiphene. AUA Male Infertility Guideline, 2021 amendment.

Neither guideline endorses compounded drug use as a first-line choice, and both emphasize the need for subspecialty evaluation before starting empiric therapy.